Schrödinger, Inc. (SDGR)
Automate Your Wheel Strategy on SDGR
With Tiblio's Option Bot, you can configure your own wheel strategy including SDGR - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol SDGR
- Rev/Share 3.2402
- Book/Share 4.6695
- PB 3.782
- Debt/Equity 0.3334
- CurrentRatio 3.2997
- ROIC -0.3535
- MktCap 1300917825.0
- FreeCF/Share 0.3319
- PFCF 53.3797
- PE -7.1511
- Debt/Assets 0.1661
- DivYield 0
- ROE -0.457
- Rating C-
- Score 1
- Recommendation Strong Sell
- P/E Score 1
- DCF Score 1
- P/B Score 2
- D/E Score 2
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Upgrade | SDGR | BofA Securities | Neutral | Buy | -- | $24 | Dec. 15, 2025 |
| Initiation | SDGR | Goldman | -- | Neutral | -- | $19 | Sept. 30, 2025 |
| Downgrade | SDGR | Citigroup | Buy | Neutral | -- | $20 | Aug. 15, 2025 |
| Initiation | SDGR | Barclays | -- | Overweight | -- | $25 | Aug. 14, 2025 |
| Resumed | SDGR | Morgan Stanley | -- | Equal Weight | -- | $28 | July 3, 2025 |
News
Schrödinger to Present at Jefferies Global Healthcare Conference
Published: May 22, 2025 by: Business Wire
Sentiment: Neutral
NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR) today announced that management will participate in a fireside chat at the Jefferies Global Healthcare Conference. The live presentation will take place on Wednesday, June 4, 2025 at 1:25 p.m. E.T. The live webcast can be accessed in the “Investors” section of Schrödinger's website and will be archived for approximately 90 days following the event. About Schrödinger Schrödinger is transforming molecular discovery with its computational.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Schrödinger, Inc. - SDGR
Published: May 21, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / May 21, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Schrödinger, Inc. ("Schrödinger" or the "Company") (NASDAQ:SDGR). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Read More
Schrödinger: Regulatory Tailwinds Are Supportive Of Continued Strong Growth (Rating Upgrade)
Published: May 20, 2025 by: Seeking Alpha
Sentiment: Positive
Schrödinger delivered strong Q1 results, with robust software growth and improving margins, despite a tough macro environment. Regulatory changes, especially the FDA's move away from animal testing, could create a meaningful tailwind for Schrödinger's predictive toxicity software initiative. Schrödinger's Drug Discovery business also continues to progress, but this likely won't matter until the company generates positive later stage clinical data.
Read More
Schrödinger to Present Phase 1 Clinical Data on MALT1 Inhibitor SGR-1505 at EHA Annual Congress and International Conference on Malignant Lymphoma
Published: May 14, 2025 by: Business Wire
Sentiment: Neutral
NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR) today announced that initial Phase 1 clinical data for SGR-1505, its investigational MALT1 inhibitor, will be presented at the European Hematology Association Annual Congress, taking place June 12 - 15, 2025, in Milan, Italy. Additional data from this trial will be presented at the International Conference on Malignant Lymphoma, taking place June 17 - 21, 2025, in Lugano, Switzerland. The Phase 1 study is designed to evaluate the safet.
Read More
Schrodinger, Inc. (SDGR) Reports Q1 Loss, Tops Revenue Estimates
Published: May 07, 2025 by: Zacks Investment Research
Sentiment: Negative
Schrodinger, Inc. (SDGR) came out with a quarterly loss of $0.82 per share versus the Zacks Consensus Estimate of a loss of $0.71. This compares to loss of $0.76 per share a year ago.
Read More
Schrödinger, Inc. (SDGR) Q1 2025 Earnings Call Transcript
Published: May 07, 2025 by: Seeking Alpha
Sentiment: Neutral
Schrödinger, Inc. (NASDAQ:SDGR ) Q1 2025 Earnings Conference Call May 7, 2025 4:30 PM ET Company Participants Jaren Madden - Senior Vice President, Investor Relations & Corporate Affairs Ramy Farid - President & Chief Executive Officer Geoff Porges - Chief Financial Officer Karen Akinsanya - President, R&D & Therapeutics Conference Call Participants Michael Yee - Jefferies Brendan Smith - TD Cowen Mani Foroohar - Leerink Partners Evan Seigerman - BMO Capital Markets Michael Ryskin - Bank of America Scott Schoenhaus - KeyBanc Vikram Purohit - Morgan Stanley Operator Thank you for standing by. Welcome to Schrödinger's conference call to review …
Read More
Schrödinger Presents New Preclinical Data at AACR Annual Meeting
Published: April 28, 2025 by: Business Wire
Sentiment: Neutral
CHICAGO--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR) presented preclinical data on SGR-3515, its investigational Wee1/Myt1 co-inhibitor today at the American Association for Cancer Research (AACR) Annual Meeting 2025. The data demonstrated that SGR-3515 has improved anti-tumor activity in preclinical models compared to known Wee1 and Myt1 monotherapy inhibitors. The poster also described how the dosing schedule of SGR-3515 can be optimized to preserve efficacy and minimize target-related.
Read More
3 Momentum Stocks That Could Soar Post-Market Volatility
Published: April 21, 2025 by: MarketBeat
Sentiment: Negative
While the impact of unanticipated tariff policy changes in early April was market-wide, the recovery has been less even. Despite a major rebound following the sell-off, some firms have been sluggish to reclaim lost ground.
Read More
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Published: April 18, 2025 by: Business Wire
Sentiment: Neutral
NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR) today reported that on April 16, 2025, the company granted (i) a non-statutory stock option to purchase 3,300 shares of the company's common stock to one newly hired employee and (ii) restricted stock units (RSUs) with respect to 12,866 shares of the company's common stock to six newly hired employees. These grants were made pursuant to the company's 2021 Inducement Equity Incentive Plan, were approved by the compensation committee of.
Read More
Schrodinger, Inc. (SDGR) Reports Q4 Loss, Tops Revenue Estimates
Published: February 26, 2025 by: Zacks Investment Research
Sentiment: Negative
Schrodinger, Inc. (SDGR) came out with a quarterly loss of $0.55 per share versus the Zacks Consensus Estimate of a loss of $0.35. This compares to loss of $0.32 per share a year ago.
Read More
About Schrödinger, Inc. (SDGR)
- IPO Date 2020-02-06
- Website https://www.schrodinger.com
- Industry Medical - Healthcare Information Services
- CEO Ramy Farid
- Employees 891